FXYD2

Across TCGA pan-cancer cohorts, FXYD2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated FXYD2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher FXYD2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FXYD2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

CCRCC and PDAC are the cancer types where FXYD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	1.000	0.758	.006	32	view →
PDAC	OS	Quartile	All	0.269	0.471	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

FXYD2–CCRCC (DFS)

Open the CCRCC breakdown →